NCT03594396View on ClinicalTrials.gov

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Breast Neoplasms

Interventions

DRUG

Olaparib

Olaparib 300mg bid will be given on days 1-28 days without rest.

DRUG

Durvalumab

A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Seoul National University Hospital

OTHER